Skip to main content Accessibility help
  • Online publication date: March 2015

Chapter 27 - Neoplastic diseases of the small and large intestines


1. Rondonotti E, Pennazio M, Toth E, et al. Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study. Endoscopy 2008; 40: 488–495.
2. Darling RC, Welch CE. Tumors of the small intestine. N Engl J Med 1959; 260: 397–401.
3. Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer 1981; 48: 799–819.
4. Olson JD, Dockerty MB, Grey HK. Benign tumors of the small bowel. Ann Surg 1951; 134: 195.
5. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010.
6. Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years Ann Surg 2009; 249: 63–71.
7. Weiss NS, Yang CP. Incidence of histologic types of cancer of the small intestine J Natl Cancer Inst 1987; 78: 653–656.
8. Gabos S, Berkel J, Band P, et al. Small bowel cancer in western Canada Int J Epidemiol 1993; 22: 198–206.
9. Welch CE, Hedberg SE. Polypoid Lesions of the Gastrointestinal Tract. Philadelphia, PA: WB Saunders; 1975.
10. Patel ND, Levy AD, Mehrotra AK, et al. Brunner’s gland hyperplasia and hamartoma: imaging features with clinicopathologic correlation. Am J Roentgenol 2006; 187: 715–722.
11. Gao YP, Zhu JS, Zheng WJ. Brunner’s gland adenoma of duodenum: a case report and literature review World J Gastroenterol 2004; 10: 2616–2617.
12. Franzin G, Musola R, Ghidini O, et al. Nodular hyperplasia of Brunner’s glands. Gastrointest Endosc 1985; 31: 374–378.
13. Levine JA, Burgart LJ, Batts KP, et al. Brunner’s gland hamartomas: clinical presentation and pathological features of 27 cases. Am J Gastroenterol 1995; 90: 290–294.
14. Kawamoto K, Motooka M, Hirata N, et al. Early primary carcinoma of the duodenal bulb arising from Brunner’s glands. Gastrointest Endosc 1994; 40: 233–235.
15. Peison B, Benisch B. Brunner’s gland adenoma of the duodenal bulb. Am J Gastroenterol 1983; 77: 276–278.
16. Nakanishi T, Takeuchi T, Hara K, et al. A great Brunner’s gland adenoma of the duodenal bulb. Dig Dis Sci 1984; 29: 81–85.
17. Amos CI, Bali D, Thiel TJ, et al. Fine mapping of a genetic locus for Peutz–Jeghers syndrome on chromosome 19p. Cancer Res 1997; 57: 3653–3656.
18. McGarrity TJ, Kulin HE, Zaino RJ. Peutz–Jeghers syndrome. Am J Gastroenterol 2000; 95: 596–604.
19. Hizawa K, Iida M, Matsumoto T, et al. Cancer in Peutz–Jeghers syndrome. Cancer 1993; 72: 2777–2781.
20. Hizawa K, Iida M, Matsumoto T, et al. Neoplastic transformation arising in Peutz–Jeghers polyposis. Dis Colon Rectum 1993; 36: 953–957.
21. van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz–Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105: 1258–1264; author reply 1265.
22. Burkart AL, Sheridan T, Lewin M, et al. Do sporadic Peutz–Jeghers polyps exist? Experience of a large teaching hospital. Am J Surg Pathol 2007; 31: 1209–1214.
23. Williams GT, Bussey HJ, Morson BC. Hamartomatous polyps in Peutz–Jeghers syndrome. N Engl J Med 1978; 299: 101–102.
24. Petersen VC, Sheehan AL, Bryan RL, et al. Misplacement of dysplastic epithelium in Peutz–Jeghers polyps: the ultimate diagnostic pitfall? Am J Surg Pathol 2000; 24: 34–39.
25. Flageole H, Raptis S, Trudel JL, et al. Progression toward malignancy of hamartomas in a patient with Peutz–Jeghers Syndrome. Case report and literature review. Can J Surg 1994; 37: 231–236.
26. Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz–Jeghers syndrome): report of a case and review of the literature. Cancer 1982; 49: 971–983.
27. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126: 1788–1794.
28. Settaf A, Mansori F, Bargach S, et al. Peutz–Jeghers syndrome with carcinomatous degeneration of a duodenal hamartomatous polyp. Ann Gastroenterol Hepatol (Paris) 1990; 26: 285–288.
29. Defago MR, Higa AL, Campra JL, et al. Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz–Jeghers syndrome. Endoscopy 1996; 28: 267.
30. Kim MH, Lee SK, Seo DW, et al. Tumors of the major duodenal papilla. Gastrointest Endosc 2001; 54: 609–620.
31. Komorowski RA, Cohen EG. Villous tumors of the duodenum: a clinicopathologic study. Cancer 1981; 47: 1377–1386.
32. Yamaguchi K, Enjoji M. Adenoma of the ampulla of Vater: putative precancerous lesion. Gut 1991; 32: 1558–1561.
33. Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3ʹ mutation in the APC gene. Gut 1998; 43: 548–552.
34. Giardiello FM, Brensinger JD, Luce MC, et al. Phenotypic expression of disease in families that have mutations in the 5ʹ region of the adenomatous polyposis coli gene. Ann Intern Med 1997; 126: 514–519.
35. Durno C, Monga N, Bapat B, et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol 2007; 5: 1190–1194.
36. Wheeler JM, Warren BF, Mortensen NJ, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut 2002; 50: 218–223.
37. Wittekind C, Tannapfel A. Adenoma of the papilla and ampulla – premalignant lesions? Langenbecks Arch Surg 2001; 386: 172–175.
38. Schulten MF, Oyasu R, Beal JM. Villous adenoma of the duodenum. A case report and review of the literature Am J Surg 1976; 132: 90–96.
39. Odze RD. Epithelial proliferation and differentiation in flat duodenal mucosa of patients with familial adenomatous polyposis. Mod Pathol 1995; 8: 648–653.
40. Agoff SN, Crispin DA, Bronner MP, et al. Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol 2001; 14: 139–146.
41. Leone BE, Taccagni GL, Dell’Antonio G, et al. Chromogranin A as a marker of neuroendocrine histogenesis of tumours: an immunoelectron microscopic study with considerations about the influence of fixation and embedding media on immunolabelling. Basic Appl Histochem 1990; 34: 143–153.
42. Dobbins WO III, Austin LL. Electron microscopic definition of intestinal endocrine cells: immunogold localization and review. Ultrastruc Pathol 1991; 15: 15–39.
43. Al-Khafaji B, Noffsinger AE, Stemmermann GN, et al. Immunohistologic analysis of carcinoid tumors: diagnostic and prognostic significance. Human Pathol 1998; 29: 992–999.
44. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005; 17: 386–391.
45. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009; 33: 626–632.
46. Long KB, Srivastava A, Hirsch MS, et al. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol 2010; 34: 723–729.
47. Cai Y-C, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol 2001; 32: 1087–1093.
48. Creutzfeldt W. Historical background and natural history of carcinoids Digestion 1994; 55)Suppl 3:) 3–10.
49. Pearse AGE, Polak JM, Bloom SR. The newer gut hormones. Cellular sources, physiology, pathology and clinical aspects. Gastroenterology 1977; 72: 746–761.
50. Pearse AGE. The APUD cell concept and its implications in pathology. Pathol Annu 1974; 9: 27–41.
51. Cheng H, Leblond CP. Origin, differentiation, and renewal of the four main epithelial cell types in the mouse small intestine. III Entero-endocrine cells. Am J Anat 1974; 141: 503–519.
52. Cheijfec G, Capella C, Solcia E, et al. Amphicrine cells, dysplasia, and neoplasias. Cancer 1985; 56: 2683–2690.
53. Williams GT. Endocrine tumours of the gastrointestinal tract-selected topics Histopathology 2007; 50: 30–41.
54. Lundquist M, Wilander E. Subepithelial neuroendocrine cells and carcinoid tumors of the human small intestine and appendix. J Pathol 1986; 148: 141–147.
55. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes 2009; 16: 72–78.
56. Kytola S, Nord B, Elder EE, et al. Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer 2002; 34: 325–332.
57. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813–829.
58. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–445.
59. Hatzaras I, Palesty JA, Abir F, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry. Arch Surg 2007; 142: 229–235.
60. Perez EA, Koniaris LG, Snell SE, et al. 7201 Carcinoids: increasing incidence overall and disproportionate mortality in the elderly world. J Surg 2007; 31: 1022–1030.
61. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–959.
62. Capella C, Riva C, Rindi G, et al. Endocrine tumors of the duodenum and upper jejunum: a study of 33 cases with clinico-pathologic characteristics and hormone content. Hepatogastroenterology 1990; 37: 247–252.
63. Kravitz RE, Balsan T, Jiminez RA. The fate of carcinoid tumors arising in Meckel’s diverticulum. Am J Gastroenterol 1962; 37: 277–282.
64. Barnardo DE, Stavrou M, Bourne R, et al. Primary carcinoid tumor of the mesentery. Hum Pathol 1984; 15: 796–798.
65. Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Somatostatin-producing duodenal carcinoids in patients with von Recklinghausen’s neurofibromatosis. A predilection for black patients. Cancer 1990; 65: 1591–1595.
66. Bornstein-Quevedo L, Gamboa-Dominguez A. Carcinoid tumors of the duodenum and ampulla of Vater: a clinicomorphologic, immunohistochemical, and cell kinetic comparison. Hum Pathol 2001; 32: 1252–1256.
67. Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18: 865–896.
68. Dayal Y, Tallberg KA, Nunnemacher G, DeLellis RA, Wolfe HJ. Duodenal carcinoids in patients with and without neurofibromatosis. A comparative study. Am J Surg Pathol 1986; 10: 348–357.
69. Attanoos R, Williams GT. Epithelial and neuroendocrine tumors of the duodenum. Semin Diagn Pathol 1991; 8: 149–162.
70. Scheithauer BW, Nora FE, LeChago J, et al. Duodenal gangliocytic paraganglioma. Clinicopathologic and immunocytochemical study of 11 cases. Am J Clin Pathol 1986; 86: 559–565.
71. Okubo Y, Wakayama M, Nemoto T, et al. Literature survey on epidemiology and pathology of gangliocytic paraganglioma. BMC Cancer 2011; 11: 187.
72. Cunningham JL, Janson ET. The biological hallmarks of ileal carcinoids. Eur J Clin Invest 2011; 41: 1353–1360.
73. Moertel CG, Sauer WG, Dockerty MB, et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901–912.
74. McNeal JE. Mechanism of obstruction in carcinoid tumors of the small intestine. Am J Clin Pathol 1971; 56: 452–458.
75. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973; 137: 637–644.
76. Beaton H, Homan W, Dineen P. Gastrointestinal carcinoids and the malignant carcinoid. Surg Gynecol Obstet 1981; 152: 268–272.
77. Norheim I, Theodorsson-Norheim, E, Brodin E, Oberg K. Tachykinins in carcinoid tumours. Their use as a tumour marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986; 63: 605–612.
78. Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 1986; 58: 2290–2293.
79. Qizilbash AH. Carcinoid tumors, vascular elastosis and ischemic disease of the small intestine. Dis Colon Rectum 1977; 20: 554–560.
80. Warner TF, O’Reilly G, Lee GA. Mesenteric occlusive lesion and ileal carcinoids. Cancer 1979; 44: 758–762.
81. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32: 107–114.
82. Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997; 113: 773–781.
83. Toliat MR, Berger W, Ropers HH, et al. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system Lancet 1997; 350: 1223.
84. Zikusoka MN, Kidd M, Eick G, et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104: 2292–2309.
85. Pizzi S, Azzoni C, Tamburini E, et al. Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability. Endocr Relat Cancer 2008; 15: 1013–1024.
86. Fujiki K, Duerr EM, Kikuchi H, et al. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology 2008; 135: 907–916.
87. Kidd M, Modlin IM, Shapiro MD, et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007; 13: 5208–5216.
88. Bordi C, D’Adda T, Azzoni C, et al. Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol 2006; 17: 119–129.
89. Chaudhry A, Oberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol 1992; 13: 27–35.
90. Greenberg RS, Baumgarten DA, Clark WS, et al. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 1987; 60: 2476–2483.
91. McDermott EWM, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007–1009.
92. Hudju SI, Winawer SJ, Myers WPL. Carcinoid tumors. A study of 204 cases. Am J Clin Pathol 1974; 61: 521–528.
93. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440–5446.
94. Connor SJ, Hanna GB, Frizell FA. Appendiceal tumors: retrospective clinico-pathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998; 41: 75–80.
95. McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer 2002; 94: 3307–3312.
96. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317: 1699–1701.
97. Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg 1993; 217: 385–390.
98. Turaga KK, Pappas SG, Gamblin TC. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012; 19: 1379–1385.
99. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 1998; 93: 422–428.
100. Whitfield C, Amin S, Garner J. Surgical management of primary appendiceal malignancy. Colorectal Dis 2012; 14: 1507–1511.
101. Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011; 104: 41–44.
102. Haqqani MT, Williams G. Mucin producing carcinoid tumours of the vermiform appendix. J Clin Pathol 1977; 30: 473–480.
103. Warkel RL, Cooper PH, Helwig EB. Adenocarcinoid, a mucin-producing carcinoid tumor of the appendix: a study of 39 cases. Cancer 1978; 42: 2781–2793.
104. Levendoglu H, Cox CA, Nadimpalli V. Composite (adenocarcinoid) tumors of the gastrointestinal tract. Dig Dis Sci 1990; 35: 519–525.
105. Warner TF, Seo IS. Goblet cell carcinoid of appendix: ultrastructural features and histogenetic aspects. Cancer 1979; 44: 1700–1706.
106. Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008; 32: 1429–1443.
107. Carr NJ, Remotti H, Sobin LH. Dual carcinoid/epithelial neoplasia of the appendix. Histopathology 1995; 27: 557–562.
108. Spread C, Berkel H, Jewell L, Jenkins H, Yakimets W. Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994; 37: 482–491.
109. El Demellawy D, Khalifa MA, Ismiil N, et al. Primary colorectal small cell carcinoma: a clinicopathological and immunohistochemical study of 10 cases. Diagn Pathol 2007; 2: 35.
110. Mills SE, Allen M, Jr, Cohen AR. Small-cell undifferentiated carcinoma of the colon. A clinicopathological study of five cases and their association with colonic adenomas. Am J Surg Pathol 1983; 7: 643–651.
111. Wang M, Peng J, Yang W, et al. Prognostic analysis for carcinoid tumours of the rectum: a single institutional analysis of 106 patients. Colorectal Dis 2011; 13: 150–153.
112. Yoon SN, Yu CS, Shin US, et al. Clinicopathological characteristics of rectal carcinoids. Int J Colorectal Dis 2010; 25: 1087–1092.
113. Makino A, Serra S, Chetty R. Composite adenocarcinoma and large cell neuroendocrine carcinoma of the rectum. Virchows Arch 2006; 448: 644–647.
114. Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008; 32: 719–731.
115. Indinnimeo M, Cicchini C, Memeo L, et al. Correlation between chromogranin-A expression and pathological variables in human colon carcinoma. Anticancer Res 2002; 22: 395–398.
116. Yao GY, Zhou JL, Lai MD, et al. Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases. World J Gastroenterol 2003; 9: 858–861.
117. Ross RK, Harnett NM, Bernstein L, et al. Epidemiology of adenocarcinomas of the small intestine: is bile a small bowel carcinogen? Br J Cancer 1991; 63: 143–145.
118. Swinson CM, Slavin G, Coles EC, et al. Coeliac disease and malignancy. Lancet 1983; 1: 111–115.
119. Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128: 590–599.
120. Jaegelman DG, DeCosse JJ, Bussey HJR. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; 1: 1149–1151.
121. Perzin KH, Peterson M, Castiglione CL. Intramucosal carcinoma of the small intestine arising in regional enteritis (Crohn’s disease). Cancer 1984; 54: 151–162.
122. Spira IA, Ghazi A, Wolff WI. Primary adenocarcinoma of the duodenum. Cancer 1977; 39: 1721–1726.
123. Bridge MF, Perzin KH. Primary adenocarcinoma of the jejunum and ileum. Cancer 1975; 36: 1876–1887.
124. Rotman N, Pezet D, Fagniez PL, et al. Adenocarcinoma of the duodenum – factors influencing survival. Br J Surg 1994; 81: 83–85.
125. Matory YL, Gaynor J, Brennan M. Carcinoma of the ampulla of Vater. Surg Gynecol Obstet 1993; 177: 366–370.
126. Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease. A population-based study. Gastroenterology 1992; 103: 954–960.
127. Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer 1981; 48: 2742–2745.
128. Fresko P, Lazarus SS, Dotan J, et al. Early presentation of carcinoma of the small bowel in Crohn’s disease. Gastroenterology 1982; 82: 783–789.
129. Nesbit RR, Elbadawi NA, Morton JH, et al. Carcinoma of the small bowel, a complication of regional enteritis. Cancer 1976; 37: 2948–2959.
130. Simpson S, Traube J, Riddell RH. The histological appearance of dysplasia (pre-carcinomatous change) in Crohn’s disease of the small and large intestine. Gastroenterology 1981; 81: 492–501.
131. Savage RA, Farmer RG, Hawk WA. Carcinoma of the small intestine associated with transmural ileitis. Am J Clin Pathol 1975; 63: 168–178.
132. Torlakovic E, Skovlund E, Snover DC, et al. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol 2003; 27: 65–81.
133. Vatn MH, Stalsberg H. The prevalence of polyps of the large intestine in Oslo. An autopsy study, Cancer 1982; 49: 819–825.
134. Tsai CJ, Lu KD. Small colorectal polyps. Histopathology and clinical significance. Am J Gastroenterol 1995; 90: 988–994.
135. Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology 1996; 110: 748–755.
136. Keljo DJ, Weinberg AG, Winick N, et al. Rectal cancer in an 11-year old with hyperplastic polyposis. J Pediatr Gastroenterol Nutr 1999; 28: 327–332.
137. Ferrandez A, Samowitz W, DiSario JA, et al. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. Am J Gastroenterol 2004; 99: 2012–2018.
138. Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer. Dis Colon Rectum 2004; 47: 2101–2104.
139. Rubio CA, Stemme S, Jaramillo E, et al. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy 2006; 38: 266–270.
140. Jass JR. Gastrointestinal polyposes: clinical, pathological and molecular features. Gastroenterol Clin North Am 2007; 36: 927–46, viii.
141. Yantiss RK, Goldman H, Odze RD. Hyperplastic polyp with epithelial misplacement (inverted hyperplastic polyp): a clinicopathologic and immunohistochemical study of 19 cases. Mod Pathol 2001; 14: 869–875.
142. Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol 2008; 32: 21–29.
143. Goldstein NS, Bhanot P, Odish E, et al. Hyperplastic-like colon polyps that preceded microsatellite-unstable adenocarcinomas. Am J Clin Pathol 2003; 119: 778–796.
144. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131: 1400–1407.
145. O’Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am 2007; 36: 947–68, viii.
146. Matsumoto T, Mizuno M, Shimizu M, et al. Clinicopathological features of serrated adenoma of the colorectum: comparison with traditional adenoma. J Clin Pathol 1999; 52: 513–516.
147. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005; 2: 398–405.
148. Jass JR. Serrated adenoma of the colorectum. A lesion with teeth. Am J Pathol 2003; 162: 705–708.
149. Shinya H, Wolff WI. Morphology, anatomic distribution and cancer potential of polyps: analysis of 7000 polyps endoscopically removed. Ann Surg 1979; 190: 679–683.
150. Pascal RR. Consistency in the terminology of colorectal dysplasia. Hum Pathol 1988; 19: 1249–1250.
151. Yantiss RK, Bosenberg MW, Antonioli DA, et al. Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma. Am J Surg Pathol 2002; 26: 206–215.
152. Kasumi A, Kratzer GL, Takeda M. Observations of aggressive, small, flat, and depressed colon cancer. Report of three cases. Surg Endosc 1995; 9: 690–694.
153. Lynch HT, Smyrk TC, Watson P, et al. Hereditary flat adenoma syndrome: a variant of familial adenomatous polyposis? Dis Colon Rectum 1992; 35: 411–421.
154. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst 2001; 93: 1282–1283.
155. Oh K, Redston M, Odze RD. Clinical, pathology and immunohistochemical characteristics of colonic mixed hyperplastic/adenomatous polyps suggests that they are a precursor to serrated adenomas. Mod Pathol 2003; 16: 119A.
156. Cooper HS, Deppisch LM, Ghourley WK, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995; 108: 1657–1665.
157. Volk EE, Goldblum JR, Petras RE, et al. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995; 109: 1801–1807.
158. Morson BC, Whiteway JE, Jones EA, et al. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut 1984; 25: 437–444.
159. Gupta SK, Fitzgerald JF, Croffie JM, et al. Experience with juvenile polyps in North American children: the need for pancolonoscopy. Am J Gastroenterol 2001; 96: 1695–1697.
160. McColl I, Bussey HJR, Vaele AMO, et al. Juvenile polyposis coli. Proc R Soc Med 1964; 57: 896–897.
161. Giardiello FM, Hamilton SR, Kern SE, et al. Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991; 66: 971–975.
162. Howe JR, Ringold JC, Summers RW, et al. A gene for familial juvenile polyposis maps to chromosome 18q21. Am J Hum Genet 1998; 62: 1129–1136.
163. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280: 1086–1088.
164. Wirtzfeld DA, Petrelli NJ, Rodriguez-Bigas MA. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann Surg Oncol 2001; 8: 319–327.
165. Wu TT, Rezai B, Rashid A, et al. Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. Am J Pathol 1997; 150: 939–947.
166. Pham BN, Villanueva RP. Ganglioneuromatous proliferation associated with juvenile polyposis coli. Arch Pathol Lab Med 1989; 113: 91–94.
167. Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5: 751–756.
168. Dunlop MC. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, juvenile polyposis, and Peutz–Jeghers syndrome. Gut 2002; 51(Ssuppl 5): V21–V27.
169. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64–67.
170. Ward EM, Wolfsen HD. Review article: the non-inherited gastrointestinal polyposis syndromes. Aliment Pharmacol Ther 2002; 16: 333–342.
171. Burke AP, Sobin LH. The pathology of Cronkhite–Canada polyps. A comparison to juvenile polyposis. Am J Surg Pathol 1989; 13: 940–946.
172. Hes FJ, Nielsen M, Bik EC, et al. Somatic APC mosaicism: an underestimated cause of polyposis coli. Gut 2008; 57: 71–76.
173. Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis Cancer 2007; 109: 761–766.
174. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot’s syndrome. N Engl J Med 1995; 332: 839–847.
175. Jass JR. Colorectal polyposes: from phenotype to diagnosis. Pathol Res Pract 2008; 204: 431–447.
176. Bertario L, Russo A, Sala P, et al. Multiple approach to the exploration of genotype–phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21: 1698–1707.
177. Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004; 127: 9–16.
178. Riegert-Johnson DL, Johnson RA, Rabe KG, et al. The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test 2007; 11: 361–365.
179. Nielsen M, de Miranda NF, van Puijenbroek M, et al. Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. BMC Cancer 2009; 9: 184.
180. van Puijenbroek M, Nielsen M, Tops CM, et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G > T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. Clin Cancer Res 2008; 14: 139–142.
181. Cleary SP, Cotterchio M, Jenkins MA, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 2009; 136: 1251–1260.
182. Lubbe SJ, Di Bernardo MC, Chandler IP, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009; 27: 3975–3980.
183. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758–1762.
184. Peltomaki P, Vasen H. Mutations associated with HNPCC predisposition – update of ICG-HNPCC/INSiGHT mutation database. Dis Mark 2004; 20: 269–276.
185. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261–268.
186. Woods MO, Williams P, Careen A, et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 2007; 28: 669–673.
187. Jass JR. Pathology of hereditary nonpolyposis colorectal cancer. Ann NY Acad Sci 2000; 910: 62–73, discussion 73–74.
188. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–543.
189. Boyle P, Langman JS. ABC of colorectal cancer: epidemiology. Br Med J 2000; 321: 805–808.
190. Kim YI. Vegetables, fruits, and colorectal cancer risk: what should we believe? Nutr Rev 2001; 59: 394–398.
191. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002; 132(Suppl): 2350S–2355S.
192. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166–174.
193. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. AA Cancer J Clin 2001; 51: 38–75.
194. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977–1981.
195. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525–532.
196. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623–627.
197. Fodde R. The APC gene in colorectal cancer. Eur J Cancer 2002; 38: 867–871.
198. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009; 16: 405–417.
199. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29: 673–680.
200. Sugai T, Habano W, Jiao YF, et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas J Mol Diagn 2006; 8: 193–201.
201. Consorti F, Lorenzotti A, Midiri G, et al. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70–74.
202. Yamamoto S, Mochizuki H, Hase K, et al. Assessment of clinocopathologic features of colorectal mucinous adenocarcinoma. Am J Surg 1993; 166: 257–261.
203. Anthony T, George R, Rodriguez-Bigas M, et al. Primary signet-ring cell carcinoma of the colon and rectum. Ann Surg Oncol 1996; 3: 344–348.
204. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009; 33: 126–133.
205. Frizelle FA, Hobday KS, Batts KP, et al. Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis Colon Rectum 2001; 44: 341–346.
206. Weidner N, Zekan P. Carcinosarcoma of the colon. Report of a unique case with light and immunohistochemical studies. Cancer 1986; 58: 1126–1130.
207. Burke AB, Shekitka KM, Sobin LH. Small cell carcinomas of the large intestine. Am J Clin Pathol 1991; 95: 315–321.
208. Nakahara H, Ishikawa T, Itabashi M, et al. Diffusely infiltrating primary colorectal carcinoma of linitis plastica and lymphangiosis types. Cancer 1992; 69: 901–906.
209. Jewell LD, Barr JR, McCaughey WT, et al. Clear-cell epithelial neoplasms of the large intestine. Arch Pathol Lab Med 1988; 112: 197–199.
210. Quirke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision Lancet 1986; 2: 996–999.
211. Reynolds JV, Joyce WP, Dolan J, et al. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996; 83: 1112–1115.
212. Nagtegaal ID, Marijne CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26: 350–357.
213. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220.
214. Hinton JM. Risk of malignant change in ulcerative colitis. Gut 1966; 7: 427–432.
215. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971; 285: 17–21.
216. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561–1567; quiz 1818–1819.
217. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228–1233.
218. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117–120.
219. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(Suppl 4): 24–30.
220. Pascal RR. Dysplasia and early carcinoma in inflammatory bowel disease and colorectal adenomas. Hum Pathol 1994; 25: 1160–1171.
221. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical implications. Hum Pathol 1983; 14: 931–968.
222. Persson P-G, Karlen P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994; 107: 1675–1679.
223. Korelitz BI, Lauwers GY, Sommers SC. Rectal mucosal dysplasia in Crohn’s disease. Gut 1990; 31: 1382–1386.
224. Odze RD. Pathology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 533–552.
225. Greenson JK. Dysplasia in inflammatory bowel disease. Semin Diagn Pathol 2002; 19: 31–37.
226. Rubio CA, Befrits R, Jaramillo E, et al. Villous and serrated adenomatous growth bordering carcinomas in inflammatory bowel disease Anticancer Res 2000; 20: 4761–4764.
227. Andersen SN, Lovig T, Clausen OP, et al. Villous, hypermucinous mucosa in long standing ulcerative colitis shows high frequency of K-ras mutations. Gut 1999; 45: 686–692.
228. Connel WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934–944.
229. Lofberg R, Bronstom O, Karlen P, et al. Colonoscopic surveillance in long-standing total ulcerative colitis – a 15-year follow-up study. Gastroenterology 1990; 99: 1021–1031.
230. Lennard-Jones JE, Ritchie JK, Morson BC. Cancer surveillance in ulcerative colitis experience over 15 years. Lancet 1983; 11: 149–152.
231. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004; 60: 334–339.
232. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 2007; 65: 998–1004.
233. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030–1038.
234. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 657–668.
235. Englesgjerd M, Farraye F, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999; 117: 1288–1294.
236. Odze R, Brown CA, Noffsinger AE, et al. Genetic alterations in chronic ulcerative colitis associated adenoma-like DALMs are similar to non-colitic sporadic adenomas. Am J Surg Pathol 2000; 24: 1202–1216.
237. Odze RD. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathologic, and molecular review. Am J Gastroenterol 1999; 94: 1746–1750.
238. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease. Am J Surg Pathol 1998; 22: 275–284.
239. Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2: 534–541.
240. Friedman S, Odze RD, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 260–266.
241. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999; 117: 1295–1300.
242. Shelton AA, Lehman RE, Schrock TR, et al. Retrospective review of colorectal cancer in ulcerative colitis at a tertiary center. Arch Surg 1996; 131: 806–810, discussion 810–811.
243. Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol 1996; 13: 339–357.
244. Lashner BA, Turner BC, Bostwick DG, et al. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990; 35: 349–352.
245. Sugita A, Greenstein AJ, Ribeiro MB, et al. Survival with colorectal cancer in ulcerative colitis. A study of 102 cases. Ann Surg 1993; 218: 189–195.
246. Goel GA, Kandiel A, Achkar JP, et al. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol 2011; 106: 719–730.
247. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006; 35: 553–571.
248. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459–465.
249. DeMatteo RP, Heinrich MC, El-Rifai, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466–477.
250. Thomas RM, Sobin LH. Gastrointestinal cancer incidence and prognosis by histologic type, SEER population-based data 1973–1987. Cancer 1995; 75: 154–170.
251. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728–734.
252. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of interstitial cells of Cajal. Am J Pathol 1998; 152: 1259–1269.
253. Russell ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979; 20: 357–459.
254. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53: 492–497.
255. Huizinga JD, Thuneberg L, Kluppel M, et al. W/kit gene required for interstitial cell of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347–349.
256. Isozaki K, Hirota S, Nakama A, et al. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995; 109: 456–464.
257. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12.
258. Majumder S, Brown K, Qiu FH, et al. c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol 1988; 8: 4896–4903.
259. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in gastrointestinal stromal tumors. Science 1998; 279: 577–580.
260. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813–3825.
261. Miettenen M, Monihan JM, Sarlomo-Rikala M. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109–1118.
262. Reith JD, Goldblum JR, Lytes RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577–585.
263. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82–87.
264. Goldblum JR, Appelman HD. Stromal tumors of the duodenum: a histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 1995; 19: 71–80.
265. Tworek JA, Appelman HD, Singleton TP, et al. Stromal tumors of the jejunum and ileum. Mod Pathol 1997; 10: 200–209.
266. Tworek JA, Goldblum JR, Weiss SW, et al. Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol 1999; 23: 937–945.
267. Tworek JA, Goldblum JR, Weiss SW, et al. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol 1999; 23: 946–954.
268. Miettenen M, Sarlomo-Rikala M, Sobin LH, et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24: 211–222.
269. Lasota J, Carlson JA, Miettenen M. Spindle cell tumor of urinary bladder serosa with phenotypic and genotypic features of gastrointestinal stromal tumor. Arch Pathol Lab Med 2000; 124: 894–897.
270. Ortiz-Hidalgo C, de Leon Bojorge B, Albores-Saavedra J. Stromal tumor of the gallbladder with phenotype of interstitial cells of Cajal. A previously unrecognized neoplasm. Am J Surg Pathol 2000; 24: 1420–1423.
271. Amin MB, Ma CK, Linden MD, et al. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors: correlation with mitotic count and clinical outcome. Am J Clin Pathol 1993; 100: 428–432.
272. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165: 107–113.
273. Mikhael A, Bacchi CE, Zarbo RJ, et al. CD34 expression in stromal tumors of the gastrointestinal tract. Appl Immunohistochem 1994; 2: 89–93.
274. Miettenen M, Virolainen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and Schwannomas. Am J Surg Pathol 1995; 19: 207–216.
275. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 477–489.
276. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484–495.
277. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70–83.
278. Morgan BK, Compton C, Talbert M, et al. Benign smooth muscle tumors of the gastrointestinal tract. Ann Surg 1990; 211: 63–66.
279. Haque S, Dean P. Stromal neoplasms of the rectum and anal canal. Hum Pathol 1992; 23: 762–767.
280. Yamada Y, Kato Y, Yana Gisawa A, et al. Microleiomyomas of human stomach. Hum Pathol 1988; 19: 569–572.
281. Miettinen M, Sobin LH, Lasota J. True smooth muscle tumors of the small intestine: a clinicopathologic, immunhistochemical, and molecular genetic study of 25 cases. Am J Surg Pathol 2009; 33: 430–436.
282. Daimaru Y, Kido H, Hashimoto H, et al. Benign Schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. Hum Pathol 1988; 19: 257–264.
283. Riccardi VM. von Recklinghausen’s neurofibromatosis. N Engl J Med 1981; 305: 1617–1627.
284. Arai T, Sugimura H, Suzuki M, et al. Benign Schwannomas of the esophagus: report of two cases with immunohistochemical and ultra-structural studies. Pathol Int 1994; 44: 460–465.
285. Hou YY, Tan YS, Xu JF, et al. Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology 2006; 48: 536–545.
286. Kirkpatrick CJ, Curry A. Interaction between mast cells and perineural fibroblasts in neurofibroma: new insights into mast cell function. Pathol Res Pract 1988; 163: 453–458.
287. Hirose T, Tani T, Shimada T, et al. Immunohistochemical demonstration of EMA/Glut1-positive perineurial cells and CD34-positive fibroblastic cells in peripheral nerve sheath tumors Mod Pathol 2003; 16: 293–298.
288. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006; 30: 90–96.
289. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen’s disease). Histopathology 1991; 19: 1–11.
290. Kheir SM, Halpern NB. Paraganglioma of the duodenum in association with congenital neurofibromatosis. Cancer 1984; 53: 2491–2496.
291. Westenend PJ, Smedts F, de Jong MC, et al. A 4-year-old boy with neurofibromatosis and severe renovascular hypertension due to renal arterial dysplasia. Am J Surg Pathol 1994; 18: 512–516.
292. Jarvis GJ, Crompton AC. Neurofibromatosis and pregnancy. Br J Obstet Gynaecol 1978; 85: 844–846.
293. Hegstrom JL, Kircher T. Alimentary tract ganglioneuromatosis–lipomatosis, adrenal myolipomas, pancreatic telangiectasias, and multinodular thyroid goiter. Am J Clin Pathol 1985; 83: 744–747.
294. Perkins JT, Blackstone MO, Riddell RH. Adenomatous polyposis coli and multiple endocrine neoplasia type 2b. Cancer 1985; 55: 375–381.
295. Weidner N, Flanders DJ, Mitros FA. Mucosal ganglioneuromatosis associated with multiple colonic polyps. Am J Surg Pathol 1984; 8: 779–786.
296. Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 1986; 10: 871–887.
297. Devroede G, Limieux B, Masse S, et al. Colonic hamartomas in tuberous sclerosis. Gastroenterology 1988; 94: 182–188.
298. Mendelsohn G, Diamond MP. Familial ganglioneuromatous polyposis of the large bowel – report of a family with associated juvenile polyposis. Am J Surg Pathol 1984; 8: 515–520.
299. Roberts JM, Yap AS, Khafagi FA, et al. Multiple endocrine neoplasia type 2b: long-term follow-up of a case. Med J Aust 1990; 153: 292–295.
300. Wirnsberger GH, Becker H, Ziervogel K, et al. Diagnostic immunohistochemistry of neuroblastic tumors Am J Surg Pathol 1992; 16: 49–57.
301. Taylor HB, Helwig EB. Benign nonchromaffin paraganglioma of the duodenum. Virchows Arch (A) 1962; 335: 356–366.
302. Kepes JJ, Zacharias DL. Gangliocytic paragangliomas of the duodenum. Cancer 1971; 27: 61–67.
303. Pertone T, Sibley RK, Rosai J. Duodenal gangliocytic paraganglioma. Am J Surg Pathol 1985; 9: 31–41.
304. Hamid QA, Bishop AE, Rode J, et al. Duodenal gangliocytic paraganglioma: a study of ten cases with immunocytochemical markers. Hum Pathol 1986; 17: 1151–1157.
305. Perrone T, Sibley RK, Rosai J. Duodenal gangliocytic paraganglioma: an immunohistochemical and ultrastructural study and a hypothesis concerning its origin. Am J Surg Pathol 1985; 9: 31–41.
306. Perrone T. Duodenal gangliocytic paraganglioma and carcinoid. Am J Surg Pathol 1986; 10: 147–149.
307. Aung W, Gallagher HJ, Joyce WP, et al. Gastrointestinal haemorrhage from a jejunal gangliocytic paraganglioma. J Clin Pathol 1995; 48: 84–85.
308. Damron TA, Rahman D, Cashman MD. Gangliocytic paraganglioma in association with a duodenal diverticulum. Am J Gastroenterol 1989; 84: 1109–1114.
309. Collina G, Maiorana A, Trentini GP. Duodenal gangliocytic paraganglioma. Case report with immunohistochemical study on the expression of keratin polypeptides. Histopathology 1991; 19: 476–478.
310. McNicol AM. Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas. Endocr Pathol 2006; 17: 329–336.
311. Grasso O, Greco P, Tricoli D, et al. Cavernous hemangioma of the colon and rectum: a case report. Tumori 1982; 68: 173–176.
312. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens – evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994; 7: 82–90.
313. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011; 35: 432–441.
314. Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue. Cancer 1981; 48: 1907–1921.
315. Nanus DM, Kelsen D, Clark DOG. Radiation-induced angiosarcoma. Cancer 1987; 60: 777–779.
316. Wolov RB, Sato N, Azumi N, et al. Intra-abdominal ‘angiosarcomatosis:’ report of two cases after pelvic irradiation. Cancer 1991; 67: 2275–2279.
317. Russo A, Virgilio C, Belluardo NB. Case of lymphangioma of the colon. Gastrointest Endosc 1983; 29: 253.
318. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2–40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol 2002; 15: 434–440.
319. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi’s sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993; 28: 371–395.
320. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi’s sarcoma. Eur J Cancer 2001; 37: 1288–1295.
321. Cheuk W, Wong KO, Wong CS, et al. Immunostaining for human herpesvirus 8 latent nuclear antigen-1 helps distinguish Kaposi sarcoma from its mimickers. Am J Clin Pathol 2004; 121: 335–342.
322. Mohandas D, Chandra RS, Srinivason V, et al. Liposarcoma of the ileum with secondaries in the liver. Am J Gastroenterol 1972; 58: 172–176.
323. Shakouh-Amini MH, Hansen CP, Moesgaard F. Liposarcoma of the stomach. A case report. Acta Chir Scand 1986; 152: 389–391.
324. Ramirez JM, Orego J, Deus J, et al. Lipomatous polyposis of the colon. Br J Surg 1993; 80: 349–350.
325. Joshi A, Chandrasoma P, Kiyabu M. Multiple granular cell tumors of the gastrointestinal tract with subsequent development of esophageal squamous carcinoma. Dig Dis Sci 1992; 37: 1612–1618.
326. Johnston J, Helwig EB. Granular cell tumors of the gastrointestinal tract and perianal region: a study of 74 cases. Dig Dis Sci 1982; 26: 807–816.
327. O’Donovan DO, Kell F. Malignant granular cell tumour with intraperitoneal dissemination. Histopathology 1989; 14: 417–419.
328. Le BH, Boyer PJ, Lewis JE, et al. Granular cell tumor: immunohistochemical assessment of inhibin-alpha, protein gene product 9.5, S-100 protein, CD68, and Ki-67 proliferative index with clinical correlation. Arch Pathol Lab Med 2004; 128: 771–775.
329. Lynch HT, Fitzgibbons R Jr. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 1996; 91: 2598–2601.
330. Gonzalez-Crussi F, Noronha R. Solitary intestinal fibromatosis in the newborn. Arch Pathol Lab Med 1985; 109: 97–99.
331. Richards RC, Rogers SW, Gardner EL. Spontaneous mesenteric fibromatosis in Gardner’s syndrome. Cancer 1981; 47: 597–601.
332. Gurbuz AK, Giardiello FM, Petersen GM. Desmoid tumours in familial adenomatous polyposis. Gut 1994; 35: 377–381.
333. Alman BA, Li C, Pajerski ME, et al. Increased b-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151: 329–334.
334. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 8: 6615–6620.
335. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51: 509–514.
336. Isaacson P, Notron AJ. Extranodal Lymphomas. New York, NY: Churchill Livingstone; 1994.
337. Kohno S, Ohshima K, Yoneda S, et al. Clinicopathological analysis of 143 primary malignant lymphomas in the small and large intestines based on the new WHO classification. Histopathology 2003; 43: 135–143.
338. Domizio P, Owen RA, Shepherd NA, et al. Primary lymphoma of the small intestine. A clinicopathologic study of 119 cases Am J Surg Pathol 1993; 17: 429–442.
339. Salem P, el-Hashimi L, Anaissie E, et al. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. Cancer 1987; 59: 1670–1676.
340. Isaacson PG. Gastrointestinal lymphomas of T- and B-cell types. Mod Pathol 1999; 12: 151–158.
341. Shepherd NA, Hall PA, Coates PJ, et al. Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathologic correlations. Histopathology 1988; 12: 235–252.
342. Wang G, Auerbach A, Wei M, et al. t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases. Mod Pathol 2009; 22: 79–86.
343. Radasziewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102: 1628–1638.
344. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105: 2274–2280.
345. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239–248.
346. Isaacson PG, Dogan A, Price SK, et al. Immunoproliferative small-intestinal disease. An immunohistochemical study Am J Surg Pathol 1989; 13: 1023–1033.
347. Kodama T, Ohshima K, Nomura K, et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology 2005; 47: 467–478.
348. Gao J, Peterson L, Nelson B, et al. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009; 132: 699–706.
349. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078.
350. Ruskone-Fourmestraux A, Delmer A, Lavergne A, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Gastroenterology 1997; 112: 7–16.
351. Chuang SS, Ye H, Du MQ, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol 2007; 128: 558–564.
352. Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma: a single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995; 21: 123–129.
353. Wright DH. Lymphoma. Cancer Surv 1997; 30: 249–261.
354. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5– T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998; 153: 1483–1490.
355. Daum S, Foss HD, Anagnostopoulous I, et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas. J Pathol 1997; 182: 311–317.
356. Ashton-Key M, Diss TC, Pan L, et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997; 151: 493–498.
357. Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992; 141: 1361–1371.
358. Burke JS. Lymphoproliferative disorders of the gastrointestinal tract: a review and pragmatic guide to diagnosis. Arch Pathol Lab Med 2011; 135: 1283–1297.
359. Moore CE, Norton LW, Meiselbaugh DM. Condyloma. Arch Surg 1978; 113: 630–631.
360. Noffsinger A, Witte D, Fenoglio-Preiser C. The relationship of human papillomaviruses to anorectal neoplasia. Cancer 1992; 70: 1276–1287.
361. Noffsinger A, Hui Y-Z, Suzuk L, et al. The relationship of human papillomavirus to proliferation and ploidy in carcinoma of the anus. Cancer 1995; 75: 958–967.
362. Zachow KR, Ostrow RS, Bender M, et al. Detection of human papillomavirus DNA in anogenital neoplasia. Nature 1983; 300: 771–773.
363. Samama B, Lipsker D, Boehm N. P16 expression in relation to human papillomavirus in anogenital lesions. Hum Pathol 2006; 37: 513–519.
364. Frazer IH, Medley G, Crapper RM, et al. Association between anorectal dysplasia, human papillomavirus and human immunodeficiency virus infection in homosexual men. Lancet 1986; 2: 657–660.
365. Palefsky JM, Holly EA, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991; 51: 1014–1019.
366. Fenger C, Nielsen VT. Precancerous changes in the anal canal epithelium in resection specimens. Acta Pathol Microbiol Immunol Scand [A] 1986; 94: 63–69.
367. Fenger C, Neilsen VT. Dysplastic changes in the anal canal epithelium in minor surgical specimens. Acta Pathol Microbiol Immunol Scand [A] 1981; 89: 463–465.
368. Bean SM, Eltoum I, Horton DK, et al. Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. Am J Surg Pathol 2007; 31: 555–561.
369. Bernard JE, Butler MO, Sandweiss L, et al. Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol 2008; 16: 215–220.
370. Dougherty BG, Evans HL. Carcinoma of the anal canal. A study of 79 cases. J Clin Pathol 1985; 83: 159–164.
371. Frisch M, Smith E, Grulich A, et al. Cancer in a population-based cohort of men and women in registered homosexual partnerships. Am J Epidemiol 2003; 157: 966–972.
372. Sawyer JL. Squamous cell cancer of the perianus and anus. Surg Clin Am 1972; 52: 935–941.
373. Preston DM, Fiona-Fowler E, Lennard-Jones JE, et al. Carcinoma of the anus in Crohn’s disease. Br J Surg 1983; 70: 346–347.
374. Slater O, Greenstein A, Aufses A Jr. Anal carcinoma in patients with Crohn’s disease. Ann Surg 1984; 199: 348–350.
375. Daling J, Sherman K, Hislop T, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992; 135: 180–189.
376. Manias DA, Ostrow RS, McGlennen RC, et al. Characterization of integrated human papillomavirus type 11 DNA in primary and metastatic tumors from a renal transplant. Cancer Res 1989; 49: 2514–2519.
377. Lecatsas O, Dreyer L, Mieny C, et al. Successive urinary papillomavirus excretion, condylomata acuminata and urogenital epithelial malignant disease after renal transplantation. S Afr Med 1985; 67: 374–376.
378. Strate RW, Richardson JD, Bannayan GA. Basosquamous (transitional cloacogenic) carcinoma of the sigmoid colon. Cancer 1977; 40: 1234–1239.
379. Cimino-Mathews A, Sharma R, Illei PB. Detection of human papillomavirus in small cell carcinomas of the anus and rectum. Am J Surg Pathol 2012; 36: 1087–1092.
380. Nigro M. An evaluation of combined therapy for squamous cell carcinoma of the anal canal. Dis Colon Rectum 1984; 27: 763–766.
381. Cutuli B, Fenton J, Labib A, et al. Anal margin carcinoma: 21 cases treated at the Institut Curie by exclusive conservative radiotherapy. Radiother Oncol 1988; 11: 1–6.
382. Clark J, Petrelli N, Herrera L, et al. Epidermoid carcinoma of the anal canal. Cancer 1986; 57: 400–406.
383. Papillon J, Montbarbon MD. Epidermoid carcinoma of the anal canal. Dis Colon Rectum 1987; 30: 324–333.
384. Magdeburg B, Fried M, Meyenberger C. Endoscopic ultrasonography in the diagnosis, staging and follow-up of anal carcinomas. Endoscopy 1999; 31: 359–364.
385. Klas JV, Rothenberger DA, Wong WD, et al. Malignant tumors of the anal canal: the spectrum of disease, treatment and outcomes. Cancer 1999; 85: 1686–1693.
386. Hung A, Crane C, Delclos M, et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97: 1195–1202.
387. Stafford SL, Martenson JA. Combined radiation and chemotherapy for carcinoma of the anal canal. Oncology 1998; 12: 373–377.
388. Friberg B, Svensson C, Goldman S, et al. The Swedish National Care Programme for anal carcinoma – implementation and overall results. Acta Oncol 1998; 37: 25–32.
389. Longacre TA, Kong CS, Welton ML. Diagnostic problems in anal pathology. Adv Anat Pathol 2008; 15: 263–278.
390. Wells M, Robertson S, Lewis F, et al. Squamous carcinoma arising in a giant peri-anal condyloma associated with human papillomavirus types 6 and 11. Histopathology 1988; 12: 319–323.
391. Gingrass JD, Bubrick MP, Hitchcock CR. Anorectal verrucose squamous carcinoma: report of two cases. Dis Colon Rectum 1978; 21: 120–122.
392. Sturm JT, Christenson CE, Uecker JH, et al. Squamous cell carcinoma of the anus arising in a giant condyloma acuminatum: report of a case. Dis Colon Rectum 1975; 18: 147–151.
393. Garrett K, Kalady MF. Anal neoplasms Surg Clin North Am 2010; 90: 147–61.
394. Basik M, Rodriguez-Bigas MA, Penetrante R, et al. Prognosis and recurrence patterns of anal adenocarcinoma. Am J Surg 1995; 169: 233–237.
395. Meriden Z, Montgomery EA. Anal duct carcinoma: a report of 5 cases. Hum Pathol 2012; 43: 216–220.
396. Kuan SF, Montag AG, Hart J, et al. Differential expression of mucin genes in mammary and extramammary Paget’s disease Am J Surg Pathol 2001; 25: 1469–1477.
397. Goldblum JR, Hart WR. Perianal Paget’s disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol 1998; 22: 170–179.
398. Bolivar J, Harris J, Branch W. Melanoma of the anorectal region. Surg Gynecol Obstet 1982; 154: 337–341.
399. Cooper PH, Mills SE, Allen S. Malignant melanoma of the anus: report of 12 patients and analysis of 255 additional cases. Dis Colon Rectum 1982; 25: 693–703.
400. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995; 38: 146–151.
401. Angeras U, Jonsson N, Jonsson P-E. Primary anorectal malignant melanoma. J Surg Oncol 1983; 22: 261–264.
402. Wanebo HJ, Woodruff JM, Farr GH. Anorectal melanoma. Cancer 1981; 47: 1891–1900.
403. Felz MW, Winburn GB, Kallab AM, et al. Anal melanoma: an aggressive malignancy masquerading as hemorrhoids. South Med J 2001; 94: 880–885.
404. Boey J, Choi TK, Wong J, et al. The surgical management of anorectal malignant melanoma. Aust NZ J Surg 1981; 51: 132–136.
405. Goldman S, Glimelius B, Pahlman L. Anorectal malignant melanoma in Sweden: report of 49 patients. Dis Colon Rectum 1990; 33: 874–877.
406. Kanaan Z, Mulhall A, Mahid S, et al. A systematic review of prognosis and therapy of anal malignant melanoma: a plea for more precise reporting of location and thickness. Am Surg 2012; 78: 28–35.